<DOC>
	<DOCNO>NCT01539941</DOCNO>
	<brief_summary>The goal proposal develop pilot brief protocol design systematically integrate pharmacological intervention attention deficit hyperactivity disorder ( ADHD ) behavioral treatment service adolescent substance user comorbid ADHD everyday care . ADHD prevalent co-occurring condition adolescent substance use ( ASU ) significantly impede successful ASU treatment vastly under-diagnosed undertreated among ASU client agency setting . Moreover , ADHD medication acceptance compliance particularly difficult achieve high-risk adolescent population .</brief_summary>
	<brief_title>Family-Based Protocol Medication Integration Treatment Comorbid ASU/ADHD Routine Care</brief_title>
	<detailed_description>The goal proposal develop pilot brief protocol design systematically integrate pharmacological intervention attention deficit hyperactivity disorder ( ADHD ) behavioral treatment service adolescent substance user comorbid ADHD everyday care . ADHD prevalent co-occurring condition adolescent substance use ( ASU ) significantly impede successful ASU treatment vastly under-diagnosed undertreated among ASU client agency setting . Moreover , ADHD medication acceptance compliance particularly difficult achieve high-risk adolescent population . The propose R21 study use interrupt time series design test brief protocol design promote integration evidence-based ADHD pharmacotherapy routine behavioral service ASU : Medication Integration Protocol ( MIP ) . MIP 5-session family-based protocol deliver early portion ASU treatment contains three research-based element : ( 1 ) standardize psychiatric assessment family-focused psychoeducation adolescent ADHD ; ( 2 ) approve ADHD medication regimen ( OROS-MPH ) demonstrate efficacy ASU/ADHD client ; ( 3 ) family-based intervention support medication acceptance ( indicate ) coordination care psychiatric behavioral service . MIP integrate exist family-based service one partner clinical site : 20 ASU/ADHD case treat site family therapists newly train monitor MIP . The partner clinic provide family therapy routine standard care outpatient behavioral health offer on-site child psychiatry service . Primary study aim yield proof-of-concept data MIP feasibility fidelity usual care evidence MIP impact psychiatric behavioral service utilization , medication acceptance compliance , satisfaction treatment service . Exploratory analysis generate effect size short-term impact MIP main target ADHD medication : ADHD symptom executive cognitive functioning . New study product would include standardized piloted MIP protocol , clinician training fidelity monitoring procedure , observational fidelity instrument . If validate , MIP could utilize stand-alone intervention everyday care , , combine exist manualized treatment ASU effort develop fully integrated treatment model ASU/ADHD . Also , MIP could deliver conjunction either family-based treatment individual treatment flexibly include caregiver early session .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<criteria>age 1317 , ( 2 ) caregiver able participate treatment , one day alcohol use intoxication illegal drug use past 30 day ( 30 day prior live control environment ) , endorsement one DSMIV symptom Substance Use Alcohol Dependence/Abuse , meet ASAM criterion outpatient substance use treatment , meet DSMIV criterion ADHD ( without onset prior age 7 ) , enrol behavioral treatment . MDD Bipolar Disorder mental retardation PDD medical psychiatric illness require hospitalization current psychotic feature current suicidality</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Co-occurring adolescent substance use ADHD</keyword>
</DOC>